San Francisco, California, November 13, 2017: A recently added report by TMR Research, titled, “Clinical Oncology Next Generation Sequencing (NGS) Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025,” throws light on key aspects of the market such as its size, competitive dynamics, and growth prospects. The report begins with basic definitions and a lowdown on classifications and applications. It studies the development history of the market along with its current competitive landscape. Beside, each key region is examined in-depth to help companies uncover lucrative markets and accordingly pitch their products and services to consumers.
Next generation sequencing (NGS), at its basic, is a DNA sequencing technology which has flipped genomic research on its head. Leveraging NGS, an entire human genome can be sequenced in just a day. The previously used Sanger sequencing technology, leveraged to unravel the human genome, needed almost more than a decade to produce the final draft. The various type of modern sequencing technologies under NSGs are illumina (Solexa) sequencing, roche 454 sequencing, proton / PGM sequencing, and SOLiD sequencing.
The different types of products and services in the global next generation sequencing (NGS) market are NGS platforms, consumables, services for platforms, sequencing services, and bioinformatics.
In NGS, billions of strands of DNA can be chained in parallel, substantially yielding more throughput and reducing the need for processes for fragment cloning. Cataloging of the genomic outlook of several oncogenes through next generation sequencing is can help uncover the exact cause of many diseases. A range of applications of next generation sequencing is predicted to boost the use of multi gene sequencing.
The domain of oncology research and treatment is expected to see good progress in the years ahead on the back of swift development of sequencing capabilities that brings about targeted sequence determination of numerous cancer genes. This makes it possible for oncologists to collect genetic information from the less accessible dense gene clusters related to the cancer cells and tumors.
Researchers for cancer have recognized the importance of next generation sequencing technology in the field of clinical oncology and are also seen expending time and money for engineering bioinformatics algorithms for development of tests pertaining to cancer and its screening.
Further, monetary support by governments through loans and grants for the purpose of research and development, especially cancer research, will positively impact the market. Proving detrimental to the global clinical oncology next generation sequencing market, on the downside, is the time consuming process and data interpretation.
Geographically, the key segments of the global clinical oncological next generation sequencing market can be divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America, among them, is a prominent market on account of the technological progress, availability of commercial solutions for NGS data analysis, and the strong presence of key players in this region. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, due to the improving healthcare infrastructure and favorable government initiatives in this region.
Some of the key companies operating in the global clinical oncological next generation sequencing (NGS) market are DNASTAR Inc., Agilent Technologies, Roche, Illumina Inc., Qiagen NV, CLC Bio, Biomatters Ltd., and Pacific Bioscience. The report studies their product offerings, sales and revenues, market shares, and prospects going forward.
Get Sample Copy of this Report